Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Oct 31, 2023 04:03PM
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 Oct 19, 2023 08:00AM
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer Oct 16, 2023 04:05PM
Pliant Therapeutics (PLRX) Reports Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Trial of Bexotegrast Sep 26, 2023 07:30AM
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Sep 26, 2023 07:30AM
View Older Stories

Sep 25, 2023 04:05PM Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Sep 15, 2023 08:01AM Pliant Therapeutics (PLRX) Appoints Minnie Kuo as Chief Development Officer
Sep 15, 2023 08:00AM Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
Sep 11, 2023 08:00AM Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
Aug 30, 2023 08:00AM Pliant Therapeutics to Participate in Upcoming Investor Conferences
Aug 28, 2023 04:05PM Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
Aug 9, 2023 04:03PM Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Aug 9, 2023 08:00AM Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
Jul 25, 2023 08:00AM Pliant Therapeutics to Participate in Upcoming Investor Conferences
Jun 23, 2023 07:30AM Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
May 24, 2023 08:04AM Pliant Therapeutics Inc. (PLRX) Presents Data from Bexotegrast Program
May 24, 2023 08:00AM Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 10, 2023 08:05AM Pliant Therapeutics to Participate in Upcoming Investor Events
May 9, 2023 04:02PM Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 1, 2023 05:22AM Pliant Therapeutics Inc. (PLRX) Reports Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial
Apr 30, 2023 02:10PM Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multi
Apr 30, 2023 02:10PM Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multi
Apr 12, 2023 08:01AM Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
Apr 12, 2023 08:01AM Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
Mar 27, 2023 08:01AM Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
Mar 27, 2023 08:01AM Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
Mar 13, 2023 08:02AM Pliant Therapeutics (PLRX) Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast
Mar 13, 2023 08:01AM Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Mar 13, 2023 08:01AM Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Mar 9, 2023 04:05PM Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
Mar 9, 2023 04:05PM Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
Mar 8, 2023 04:01PM Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
Mar 8, 2023 04:01PM Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
Mar 1, 2023 08:01AM Pliant Therapeutics to Participate in Upcoming Investor Events
Mar 1, 2023 08:01AM Pliant Therapeutics to Participate in Upcoming Investor Events
Feb 7, 2023 08:01AM Pliant Therapeutics to Participate in Upcoming Investor Events
Feb 7, 2023 08:01AM Pliant Therapeutics to Participate in Upcoming Investor Events
Feb 2, 2023 08:03AM Pliant Therapeutics Inc. (PLRX) Announces FDA Clearance of IND for PLN-101095
Feb 2, 2023 08:02AM Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Feb 2, 2023 08:02AM Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Jan 25, 2023 08:01AM Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
Jan 25, 2023 08:01AM Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
Jan 23, 2023 05:44AM Pliant Therapeutics Inc. (PLRX) Reports Positive Data from INTEGRIS-IPF Phase 2a Trial of Bexotegrast
Jan 22, 2023 02:00PM Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients wit
Jan 22, 2023 02:00PM Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients wit
Jan 3, 2023 08:00AM Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 08:00AM Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Dec 15, 2022 08:08AM Pliant Therapeutics (PLRX) Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Dec 15, 2022 08:00AM Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Dec 15, 2022 08:00AM Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Nov 15, 2022 08:00AM Pliant Therapeutics to Participate in Upcoming Investor Conferences
Nov 15, 2022 08:00AM Pliant Therapeutics to Participate in Upcoming Investor Conferences
Nov 8, 2022 04:02PM Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Nov 8, 2022 04:02PM Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Oct 5, 2022 08:00AM Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
View Older Stories